142 filings
Page 5 of 8
8-K
c0eg744 g8mfzgfnu5
1 Aug 18
Mirati Therapeutics Reports Second Quarter
4:25pm
8-K
gydvvz qu5crd7
7 Jun 18
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
4:03pm
8-K
zxtwhj3t tu
18 May 18
Submission of Matters to a Vote of Security Holders
4:26pm
8-K
wgbjtt
7 May 18
Mirati Therapeutics Reports First Quarter
4:31pm
8-K
w268hmqxwk 88
24 Apr 18
Mirati Therapeutics Announces Progress of Lead Programs
12:00am
8-K
4kzqu3k0wy
10 Apr 18
Entry into a Material Definitive Agreement
12:00am
8-K
tkz9v9
8 Mar 18
Mirati Therapeutics Reports Fourth Quarter and Full-year 2017 Financial Results
12:00am
8-K
ehu4 x96k
24 Jan 18
Departure of Directors or Certain Officers
12:00am
8-K
klxgxf
11 Jan 18
BeiGene and Mirati Therapeutics Announce Exclusive License Agreement for Sitravatinib in the Asia Pacific Region
12:00am
8-K
p07r1e0
16 Nov 17
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
12:00am
8-K
6hg 6lznbyaot
13 Nov 17
Mirati Therapeutics Announces Advancement of First-in-class Opportunities with Sitravatinib and Kras Inhibitor Programs
12:00am
8-K
gtvn7zg8mgkgpcspzw
1 Nov 17
Mirati Therapeutics Reports Third Quarter 2017
12:00am
8-K
1m6a vol7sjo7387
14 Sep 17
Mirati Therapeutics Presents Positive Preliminary
12:00am
8-K
tnl66zug
3 Aug 17
Mirati Therapeutics Reports Second Quarter 2017
12:00am
8-K
gwhfrhjmeh wf
27 Jun 17
Mirati Therapeutics Announces Appointment of
12:00am
8-K
2ysmiebg op5
19 May 17
Departure of Directors or Certain Officers
12:00am
8-K
hiyl 5phgxmk
4 May 17
Mirati Therapeutics Reports First Quarter 2017
12:00am
8-K
qud14ff2osngw
27 Mar 17
Entry into a Material Definitive Agreement
12:00am
8-K
yggp7
9 Mar 17
Mirati Therapeutics Reports Financial Results and Provides Business
12:00am
8-K
ux6yq 3gg
1 Feb 17
Departure of Directors or Certain Officers
12:00am